ClinicalTrials.gov
public full text
Public Domain
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation
To compare the efficacy and safety of Lenvatinib combined with the standard Stupp regimen versus the standard Stupp regimen alone in the treatment of newly diagnosed glioblastoma with MGMT promoter methylation positive.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients#1060363
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)#1138592
- A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme#1171612
- Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma#1095713
- 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma#1058202
Record · ID 1213472
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive